Obrixtamig not checked
Boehringer Ingelheim · BI 764532
FollowEvery change as it happens, and a Monday email
Trials
13 active
13 in total · 11 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- Tested for
- Neuroendocrine Neoplasms (4 trials), Small Cell Lung Carcinoma (SCLC) (4 trials), Advanced Cancer, Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extrapulmonary Neuroendocrine Cancer (epNEC), Small Cell Lung Carcinoma, Extra-pulmonary Neuroendocrine Carcinoma and 8 more
- Main trialPhase 3
- “This study is open to adults with advanced cancer who received obrixtamig (BI 764532) in one of several previous studies and benefited from treatment. The goal of this study is to find out how well participants who received obrixtamig in a previous study tolerate obrixtamig. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Participants in this study continue receiving obrixtamig and any other study or standard of care anti-cancer medicines they received in their previous study at the same doses and following the same treatment schedule. Treatments are…”In the company’s words, NCT07929051 on ClinicalTrials.gov
- Other names
- BI 764532
Other drugs for Neuroendocrine Neoplasms
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- UpadacitinibAbbVie · Phase 3
- Viaskin PeanutDBV Technologies · Phase 3
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- Budesonide orodispersible tabletDr. Falk Pharma GmbH · Phase 3
Coming up11
- 15 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 9 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 9 Oct 2027Phase 1 trial completes · ClinicalTrials.gov
- 17 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 3 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 9 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 13 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 17 Apr 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 26 Apr 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07707895
- 10 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07929051
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 3 Jul 2028 | A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig | |
| Phase 3Recruiting | 9 Sep 2028 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | |
| Phase 3Recruiting | 13 Dec 2029 | DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | |
| Phase 2Recruiting | 17 Dec 2027 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | |
| Phase 1/2Recruiting | 17 Apr 2030 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | |
| Phase 1/2Recruiting | 26 Apr 2030 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | |
| Phase 1Active, not recruiting | 11 Jun 2025 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | |
| Phase 1Active, not recruiting | 31 Aug 2026 | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | |
| Phase 1Recruiting | 15 Dec 2026 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | |
| Phase 1Active, not recruiting | 30 Mar 2027 | DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy | |
| Phase 1Active, not recruiting | 31 Mar 2027 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer | |
| Phase 1Recruiting | 9 Aug 2027 | A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | |
| Phase 1Active, not recruiting | 9 Oct 2027 | DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026